1. nd
2 Monoclonal Antibodies
Exploring innovation in therapeutic antibody development and production
March 19‐20, Novotel West London Hotel, London UK
Exploring Innovation in therapeutic antibody development & production
19th – 20th March 2013, Novotel West London Hotel, UK BOOK NOW!
Key Speakers
• Dr Carrie Enevar, Investigator, GlaxoSmithKline
• Dr Yasmina Abdiche, Associate Research Fellow, Pfizer
• Dr Steffen Hartmann, Head of Protein Deveopability, Novartis
• Dr Rebecca Croasdale, Oncology Scientist, Hoffmann­La­Roche
• Dr Olga Obrezanova, Principle Scientist, Lonza Biologics
• Dr Marcel Kuiper, Senior Scientist, MedImmune
• Dr Nicola Beltraminelli, Head of Antibody Discovery Unit, Vivalis
• Dr Richard Schasfoort, CSO, IBIS Technologies B.V
• Dr Pim Hermans, Director of Ligand Discovery, BAC bv
• Dr Brian Burke, Business Development Manager, Horizon Discovery Ltd
• Dr Mark Throsby, Chief Operating Officer, Merus
• Dr Hans de Haard, Chief Scientific Officer, Argenx
• Dr Maria G‐Pajuelo, Chief Scientific Officer, Fairjourney Biologics
• Dr Nico Mertens, Director of Antibody Engineering, Biotechnol
• Dr Andrew Martin, Senior lecturer, UCL
• Dr Marguerite M‐Harsema, Project Manager, Medac
• Dr Louis Boon, Chief Scientific Officer, Bioceros
Driving the Industry Forward www.futurepharmaus.com
Media Partners
For Booking please contact +44 0207 718 018989 | www.appelconsulting.co.uk

2. Day 1
Monoclonal Antibodies Summit
Tuesday 19th March 2013
09:00 Registration and refreshments 12:40 Networking lunch
09:30 Opening address from the chair
Dr Yasmina Abdiche 13.40 Exploiting the modularity of domain
Associate Research Fellow antibodies to advance biotherapeutic
Pfizer platforms
09:40 Beyond monoclonals: process • Modality driven selection of lead domain antibodies
development challenges
• Case studies focused on key considerations to achieve optimal
• Monoclonal Antibodies PK/PD and developability
• Bi-specific antibodies
• Manufacturing process development Dr Carrie Enevar
Investigator
GlaxoSmithKline
Dr Marcel Kuiper
Senior Scientist
MedImmune
14:20 Rapid high throughput discovery of Native Therapeutic
Monoclonal Antibodies
10:20 Characterizing monoclonal antibodies using • Use Human primary B Lymphocytes
label-free biosensors
• Throughput discovery
• Expanding the proteOn XPR36 into a 36 ligand array • Therapeutic Monoclonal Antibodies
• Kinetics epitope binning and epitope mapping Dr Nicola Beltraminelli
Head of Antibody Discovery Unit
• Biocore , ProteOn and Octect technologies Vivalis
Dr Yasmina Abdiche
Associate Research Fellow
Pfizer
15:00 Tribodies for two-in-one biospecific antibody fragments
• Why tribodies
11:00 Morning refreshments • Biotecnol’s developmental capabilities
• Tribody pipeline examples
Dr Nico Mertens
11:20 Immunogenicity and stability assessment for
Director of Antibody Research
monoclonal antibodies Biotecnol
• In silico and in vitro immunogenicity assessment
• Deimminisation and humanization
• Engineering to reduce aggregation and improve stability
Dr Olga Obrezanova
Principle Scientist
Lonza
12:00 Glycoengineered IGF-1R-EGFR biospecific antibodies 15:40 End of conference for day one.
• Effective antibodies
15:50 Networking drinks
• Antibody engineering
Take your discussions further and build new
• Effector Functions relationships in a relaxed and informal setting.
Dr Rebecca Croasdale
Oncology Scientist Officer
Roche

3. Day 2
Monoclonal Antibodies Summit
Wednesday 20th March 2013
09:00 Registration and refreshments 13:40 Bispecific IgG-based therapy of hematological and solid
tumors serum half-life
09:30 Opening address from the chair • Human antibody transgenic mouse
Dr Yasmina Abdiche
• Bispecific antibodies
Associate Research Fellow
Pfizer • Multi specific targeting in oncology
09:40 Kinetic rate & affinity constant screening of Dr Mark Thosby
engineered antibodies using the IBIS MX96 COO
• Surface Plasmon Resonance Imaging (SPRi) Merus
• Single molecular affinity screening (KDR0) 13:40 CD70: A new compelling immune modulatory target for the
• Binding 48 antibodies in a day treatment of cancer
Dr Richard Schasfoort • CD70 mAb ARGX-110
Chief Scientific Officer • NHance for serum half life extension
• New bispecifoc approach
IBIS Technologies
Dr Hans de Haard, CSO, Argenx
10:20 Phage display-based directed generation of
mAbs: the journey & services around
14:00 Monoclonal Antibodies the future: a decade at a
• Phage display
glance
• Discovery
Our expert panel will discuss and debate on:
• Humanization
Generation of highly specific & functional mAbs and the future
Dr Maria G-Pajuelo
development and applications of mAbs over the next ten years.
Chief Scientific Officer
Panel members will be drawn from the speakers who take part on day one
Fairjourney biologics
or day two
11:00 Morning refreshments
Dr Yasmina Abdiche
Associate Research Fellow
11:20 Use of homologous recombinant based
Pfizer
gene engineering for CHO cell line
optimization Dr Carrie Enevar
Investigator
GlaxoSmithKline
• Cell line engineering and improving infection
• Cell line platforms for vaccine production Dr Richard Schasfoort
• Gene correction/modification Chief Scientific Officer
Dr Brian Burke IBIS Technologies
Business Development Manager
Horizon Discovery Ltd
12:00 Next generation antibody analytics
• Antibody subdomain specific affinity ligands
• Antibody capture tools for screening kinetics
• Detection, quantication and purification of antibody formats
15:00 Chair’s closing remarks
Dr Pim Hermans
Director of Ligand Discovery 15:10 End of conference
BAC bv
12:40 Networking lunch